Galectin Therapeutics Inc (GALT) CFO Sells $16,745.00 in Stock

Galectin Therapeutics Inc (NASDAQ:GALT) CFO Jack W. Callicutt sold 3,349 shares of the firm’s stock in a transaction on Wednesday, April 4th. The stock was sold at an average price of $5.00, for a total transaction of $16,745.00. Following the completion of the sale, the chief financial officer now owns 4,609 shares in the company, valued at approximately $23,045. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Galectin Therapeutics stock traded up $0.11 during midday trading on Friday, hitting $4.68. The company had a trading volume of 260,084 shares, compared to its average volume of 661,166. Galectin Therapeutics Inc has a 1-year low of $1.28 and a 1-year high of $6.74. The company has a market cap of $178.08, a price-to-earnings ratio of -9.55 and a beta of 2.53.

How to Become a New Pot Stock Millionaire

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Thursday, March 29th. The company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.04. analysts anticipate that Galectin Therapeutics Inc will post -0.48 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wedbush Securities Inc. acquired a new stake in Galectin Therapeutics during the fourth quarter worth $102,000. Vanguard Group Inc. boosted its stake in Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after buying an additional 134,165 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after buying an additional 3,176 shares in the last quarter. Hedge funds and other institutional investors own 10.29% of the company’s stock.

Several brokerages have recently issued reports on GALT. ValuEngine downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 6th. Roth Capital lowered their price objective on shares of Galectin Therapeutics from $10.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, December 7th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective (up previously from $6.00) on shares of Galectin Therapeutics in a research note on Thursday, December 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $6.44.

WARNING: “Galectin Therapeutics Inc (GALT) CFO Sells $16,745.00 in Stock” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3336276/galectin-therapeutics-inc-galt-cfo-sells-16745-00-in-stock.html.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Brokerages Expect Energy Transfer Partners  to Announce $0.26 EPS
Zacks: Brokerages Expect Energy Transfer Partners to Announce $0.26 EPS
Clean Energy Fuels  Given Daily Media Impact Rating of -0.02
Clean Energy Fuels Given Daily Media Impact Rating of -0.02
Somewhat Favorable News Coverage Somewhat Unlikely to Affect Monroe Bank & Trust  Share Price
Somewhat Favorable News Coverage Somewhat Unlikely to Affect Monroe Bank & Trust Share Price
Northrim BanCorp  Receiving Positive Media Coverage, Analysis Shows
Northrim BanCorp Receiving Positive Media Coverage, Analysis Shows
ArQule  Getting Somewhat Favorable Press Coverage, Accern Reports
ArQule Getting Somewhat Favorable Press Coverage, Accern Reports
Franko Market Capitalization Tops $115,130.00
Franko Market Capitalization Tops $115,130.00


© 2006-2018 Ticker Report. Google+.